At a glance
- Originator Astellas Pharma
- Class Antiasthmatics; Small molecules; Surfactants
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
- 14 May 1998 Phase-II clinical trials for Chronic obstructive pulmonary disease in European Union (PO)
- 29 Apr 1997 Phase-I clinical trials for Chronic obstructive pulmonary disease in European Union (PO)